

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Sulfur Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713926081>

An efficient synthesis of stable sulfur-containing phosphoranes derived from 2-mercapto-1-methylimidazole and 2-thiazoline-2-thiol

M. T. Maghsoodlou^a; N. Hazeri^a; S. M. H. Khorassani^a; M. Nassiri^a; G. Marandi^a; G. Afshari^a; U. Niroumand^a

^a Department of Chemistry, The University of Sistan and Balouchestan, Zahedan, Iran

To cite this Article Maghsoodlou, M. T. , Hazeri, N. , Khorassani, S. M. H. , Nassiri, M. , Marandi, G. , Afshari, G. and Niroumand, U.(2005) 'An efficient synthesis of stable sulfur-containing phosphoranes derived from 2-mercapto-1-methylimidazole and 2-thiazoline-2-thiol', *Journal of Sulfur Chemistry*, 26: 3, 261 – 265

To link to this Article: DOI: 10.1080/17415990500276238

URL: <http://dx.doi.org/10.1080/17415990500276238>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

RESEARCH ARTICLE

An efficient synthesis of stable sulfur-containing phosphoranes derived from 2-mercapto-1-methylimidazole and 2-thiazoline-2-thiol

M. T. MAGHSOODLOU*, N. HAZERI, S. M. H. KHORASSANI, M. NASSIRI,
G. MARANDI, G. AFSHARI and U. NIROUMAND

Department of Chemistry, The University of Sistan and Balouchestan, P. O. Box 98135-674,
Zahedan, Iran

(Received 6 March 2005; in final form 13 May 2005)

Stable crystalline phosphorus ylides were obtained in excellent yields from the 1:1:1 addition reaction between triphenylphosphine and dialkyl acetylenedicarboxylates in the presence of strong SH-acids, such as 2-mercapto-1-methylimidazole and 2-thiazoline-2-thiol. These stable ylides exist in solution as a mixture of two geometrical isomers as a result of restricted rotation around the carbon–carbon partial double bond resulting from conjugation of the ylide moiety with the adjacent carbonyl group.

Keywords: Stable phosphorus ylide; Acetylenic esters; 2-Mercapto-1-methylimidazole and 2-Thiazoline-2-thiol; Triphenylphosphine; Geometrical isomers


1. Introduction

Phosphorus ylides are reactive systems which take part in many valuable reactions of organic synthesis [1–11]. These are most often prepared by treatment of a phosphonium salt with a base. Most of the phosphonium salts are usually made from the phosphine and an alkyl halide [1–5] and they are also obtained by Michael addition of phosphorus nucleophiles to activated olefins [1, 2]. Here, we describe an efficient synthetic route of the 2-mercapto-1-methylimidazole and also the 2-thiazoline-2-thiol-containing stable phosphorus ylides [12]. As has been noted earlier, the imidazole moiety and its derivatives are widely used in making medicines, and they also have biological activity [13]. Moreover, the thiazolines have antitumor properties [13].

With respect to the importance of the aforementioned purpose the present work was undertaken for the generation of stable sulfur-containing phosphoranes. In order to do this, the reaction of triphenylphosphine with dialkyl acetylenedicarboxylates (**1**) in the presence of

*Corresponding author. Tel: +98-541-2446565; Email: mt_maghsoodlou@yahoo.com

strong SH-acids (**2**) and (**5**) led to the vinyltriphenylphosphonium cation (**3**), which was subsequently followed by attack of the 2-mercapto-1-methylimidazole or 2-thiazoline-2-thiol anion to form the phosphoranes (**4-E**), (**4-Z**), (**6-E**), and (**6-Z**) in excellent yields (see scheme 1).



SCHEME 1


2. Results and discussion

The reactions of 2-mercapto-1-methylimidazole and 2-thiazoline-2-thiol with dialkyl acetylenedicarboxylates (**1**) in the presence of triphenylphosphine were carried out in ethyl acetate solvent at room temperature and were complete after approximately 8 hours.

The ¹H and ¹³C NMR spectra of the crude product clearly indicated the formation of phosphoranes (**4**) and (**6**). Any products other than (**4**) and (**6**) could not be detected by NMR spectroscopy. The ¹³C NMR spectrum of compounds (**4a**) and (**6a**) exhibited a signal at δ (162.02) ppm and (195.25) ppm for the N-C-S and C=S units, respectively [14].

The structures of compounds (**4a-c**) and (**6a-c**) were deduced from their IR, ¹H, ¹³C, and ³¹P NMR spectra. Their mass spectra displayed molecular ion peaks at appropriate *m/z* values. Any initial fragmentations involve loss of the side chains. The ¹H, ¹³C, and ³¹P NMR

spectra of ylides (**4a** and **b**) and (**6a** and **b**) are consistent with the presence of two isomers, but only one geometrical isomer was observed for the di-*tert*-butyl derivatives (**4c**) and (**6c**), presumably because of the bulky *tert*-butyl group. The ylide moiety of these compounds is strongly conjugated with the adjacent carbonyl group, and rotation around the partial double bond in (**4-E**), (**4-Z**), (**6-E**), and (**6-Z**) geometrical isomers is slow on the NMR timescale at ambient temperature (see scheme 2). ^{31}P NMR chemical shifts and coupling constants in the major (M) and minor (m) geometrical isomers of compounds (**4a-c**) and (**6-c**) were described in the experimental section.



SCHEME 2

3. Experimental

Mps and IR spectra of all compounds were measured on an Electrothermal 9100 apparatus and a Shimadzu IR-460 spectrometer, respectively. ^1H , ^{13}C , and ^{31}P NMR spectra were obtained from a Bruker DRX-500 Avance instrument with CDCl_3 as solvent at 500.1, 125.8, and 202.4 MHz, respectively. Mass spectra were recorded on a Shimadzu QP 1100 EX mass spectrometer operating at an ionization potential of 70 eV. Triphenylphosphine, dialkyl acetylenedicarboxylates (**1a-c**), 2-mercapto-1-methylimidazole (**2**), and 2-thiazoline-2-thiol (**5**) were purchased from Fluka (Buchs, Switzerland) and used without further purification.

3.1 Preparation of dimethyl 2-(1-methylimidazole-2-sulfanyl)-3-(triphenylphosphanylidene) butanedioate (**4a**)

General procedure. To a magnetically stirred solution of 2-mercapto-1-methylimidazole (0.11 g, 1 mmol) and triphenylphosphine (0.26 g, 1 mmol) in 8 mL of ethyl acetate was added, dropwise, a mixture of dimethyl acetylenedicarboxylate (0.14 g, 1 mmol) in 4 mL of ethyl acetate at -5°C over 10 min. After approximately 8 hours of stirring at room temperature, the product was washed with cold diethyl ether (5 mL) and extracted as colorless crystals (0.50 g,

97%), mp 205–206 °C; IR (ν_{\max} , cm^{-1}) 1740, 1620 (C=O); MS (m/z , %) 459 (M - CO₂Me, 15), 405 (M - heterocyclic, 50), 262 (PPh₃, 38), 183 (PPh₂, 18), 108 (PPh, 25), 77 (Ph, 6).

Major isomer (*E*)-**4a** (65%): ¹H NMR (500.1 MHz; CDCl₃) δ 3.12 (3H, s, NCH₃), 3.48 and 3.74 (6H, 2s, 2 OCH₃), 5.55 (1H, d, ³J_{PH} 17.2 Hz, P-C-CH), 6.62 and 7.28 (2s, 2 H_{arom}, C₃H₂N₂S), 7.48–7.66 (15H, m, C₆H₅). ¹³C NMR (125.8 MHz; CDCl₃) δ 34.62 (s, NCH₃), 43.35 (d, ¹J_{PC} 128.2 Hz, P=C), 49.21 and 52.62 (2s, 2 OCH₃), 60.40 (d, ²J_{PC} 18.5 Hz, P-C-CH), 116.77 and 117.38 (2C, C₃H₂N₂S), 126.35 (d, ¹J_{PC} 92.2 Hz, C_{ipso}), 128.99 (d, ³J_{PC} 11.8 Hz, C_{meta}), 132.25 (C_{para}), 133.61 (d, ²J_{PC} 9.8 Hz, C_{ortho}), 162.03 (1C, C₃H₂N₂S, N-C-S), 170.35 (d, ³J_{PC} 12.7 Hz, C=O), 171.56 (d, ²J_{PC} 10.8 Hz, P-C=C). ³¹P NMR (202.4 MHz; CDCl₃) δ 24.09 (Ph₃P⁺-C).

Minor isomer (*Z*)-**4a** (35%): ¹H NMR (500.1 MHz; CDCl₃) δ 3.13 (3H, s, NCH₃), 3.50 and 3.58 (6H, 2s, 2 OCH₃), 5.48 (1H, d, ³J_{PH} 18.7 Hz, P-C-CH), 6.67 and 7.29 (2s, 2 H_{arom}, C₃H₂N₂S), 7.49–7.67 (15H, m, C₆H₅). ¹³C NMR (125.8 MHz; CDCl₃) δ 34.60 (s, NCH₃), 43.33 (d, ¹J_{PC} 128.4 Hz, P=C), 50.22 and 52.50 (2s, 2 OCH₃), 60.23 (d, ²J_{PC} 24.7 Hz, P-C-CH), 116.11 and 116.76 (2C, C₃H₂N₂S), 125.61 (d, ¹J_{PC} 93.1 Hz, C_{ipso}), 128.51 (d, ³J_{PC} 12.2 Hz, C_{meta}), 132.23 (C_{para}), 133.60 (d, ²J_{PC} 9.8 Hz, C_{ortho}), 162.43 (1C, C₃H₂N₂S, N-C-S), 170.34 (d, ³J_{PC} 12.7 Hz, C=O), 171.23 (d, ²J_{PC} 12.1 Hz, P-C=C). ³¹P NMR (202.4 MHz; CDCl₃) δ 24.81 (Ph₃P⁺-C).

3.2 Preparation of diethyl 2-(1-methylimidazole-2-sulfanyl)-3-(triphenylphosphanylidene) butanedioate (**4b**)

White powder (0.51 g, 94%), mp 109–111 °C; IR (ν_{\max} , cm^{-1}) 1730, 1620 (C=O); MS (m/z , %) 433 (M-heterocyclic, 100), 284 (M-PPh₃, 8), 262 (PPh₃, 65), 211 (M-PPh₃-CO₂Et, 9), 182 (M-PPh₃-CO₂Et-Et, 45), 183 (PPh₂, 21), 108 (PPh, 79), 77 (Ph, 7).

Major isomer (*E*)-**4b** (72%): ¹H NMR (500.1 MHz; CDCl₃) δ 0.47 and 1.31 (6H, 2t, ³J_{HH} 7.0 Hz and 7.1 Hz, 2 O-C-CH₃), 3.51 (3H, s, NCH₃), 3.77 and 4.30 (4H, 2m, 2 ABX₃ system, 2 O-CH₂-C), 5.54 (1H, d, ³J_{PH} 17.5 Hz, P-C-CH), 6.62 and 7.36 (2s, 2 H_{arom}, C₃H₂N₂S), 7.50–7.70 (15H, m, 3 C₆H₅). ¹³C NMR (125.8 MHz; CDCl₃) δ 14.02 and 14.90 (2s, 2 O-C-CH₃), 34.63 (s, NCH₃), 43.11 (d, ¹J_{PC} 127.0 Hz, P=C), 60.37 (d, ²J_{PC} 17.9 Hz, P-C-CH), 61.32 and 61.37 (2C, 2 OCH₂CH₃), 116.63 and 117.59 (2C, C₃H₂N₂S), 126.54 (d, ¹J_{PC} 91.3 Hz, C_{ipso}), 128.51 (d, ³J_{PC} 12.1 Hz, C_{meta}), 131.95 (d, ⁴J_{PC} 2.6 Hz, C_{para}), 132.10 (d, ²J_{PC} 9.8 Hz, C_{ortho}), 161.98 (1C, C₃H₂N₂S, N-C-S), 169.37 (d, ³J_{PC} 13.0 Hz, C=O), 170.85 (d, ²J_{PC} 13.4 Hz, P-C=C). ³¹P NMR (202.4 MHz; CDCl₃) δ 23.03 (Ph₃P⁺-C).

Minor isomer (*Z*)-**4b** (28%): ¹H NMR (500.1 MHz; CDCl₃) δ 1.19 and 1.35 (6H, 2t, ³J_{HH} 6.7 Hz and 6.9 Hz, 2 OCH₂CH₃), 3.53 (3H, s, NCH₃), 3.69 and 4.20 (4H, 2m, 2 ABX₃ system, 2 OCH₂CH₃), 5.49 (1H, d, ³J_{PH} 19.1 Hz, P-C-CH), 6.67 and 7.29 (2s, 2 H_{arom}, C₃H₂N₂S), 7.50–7.70 (15H, m, 3 C₆H₅). ¹³C NMR (125.8 MHz; CDCl₃) δ 13.91 and 14.01 (2s, 2 O-C-CH₃), 34.33 (s, NCH₃), 43.13 (d, ¹J_{PC} 127.0 Hz, P=C), 60.35 (d, ²J_{PC} 18.0 Hz, P-C-CH), 61.23 and 61.32 (2s, 2 OCH₂CH₃), 116.65 and 117.61 (2C, C₃H₂N₂S), 125.82 (d, ¹J_{PC} 90.2 Hz, C_{ipso}), 128.90 (d, ³J_{PC} 12.2 Hz, C_{meta}), 131.97 (d, ⁴J_{PC} 2.6 Hz, C_{para}), 132.12 (d, ²J_{PC} 9.9 Hz, C_{ortho}), 163.26 (1C, C₃H₂N₂S, N-C-S), 169.70 (d, ³J_{PC} 13.0 Hz, C=O), 170.83 (d, ²J_{PC} 15.8 Hz, P-C=C). ³¹P NMR (202.4 MHz; CDCl₃) δ 23.99 (Ph₃P⁺-C).

3.3 Preparation of di-tert-butyl 2-(1-methylimidazole-2-sulfanyl)-3-(triphenylphosphanylidene) butanedioate (**4c**)

White powder (0.57 g, 97%), mp 162–164 °C; IR (ν_{\max} , cm^{-1}) 1730, 1620, (C=O); MS (m/z , %) 488 (CO₂CMe₃, 22), 476 (M-heterocyclic, 30), 262 (PPh₃, 54), 183 (PPh₂, 30), 108 (PPh, 67).

Major rotamer (*E*)-**4c**: ^1H NMR (500.1 MHz; CDCl_3) δ 0.97 and 1.54 (18H, 2s, 2 CMe_3), 3.47 (3H, s, N- CH_3), 5.33 (1H, d, $^3J_{\text{PH}}$ 17.7 Hz, P-C-CH), 6.61 (s, H_{arom} , $\text{C}_3\text{H}_2\text{N}_2\text{S}$), 7.47–7.68 (16H, m, 3 C_6H_5 and $\text{C}_3\text{H}_2\text{N}_2\text{S}$). ^{13}C NMR (125.8 MHz; CDCl_3) δ 28.24 and 28.30 (2s, 2 CMe_3), 34.81 (s, N CH_3), 42.42 (d, $^1J_{\text{PC}}$ 127.9 Hz, P=C), 61.01 (d, $^2J_{\text{PC}}$ 18.3 Hz, P-C-CH), 77.56 and 80.89 (2s, 2 OCMe_3), 116.50 and 116.73 (2C, $\text{C}_3\text{H}_2\text{N}_2\text{S}$), 127.06 (d, $^1J_{\text{CP}}$ 92.1 Hz, C_{ipso}), 128.76 (d, $^3J_{\text{PC}}$ 12.2 Hz, C_{meta}), 132.12 (C_{para}), 133.68 (d, $^2J_{\text{PC}}$ 9.7 Hz, C_{ortho}), 161.92 (1C, N-C-S, $\text{C}_3\text{H}_2\text{N}_2\text{S}$), 169.28 (d, $^3J_{\text{PC}}$ 12.5 Hz C=O), 169.33 (d, $^2J_{\text{PC}}$ 11.4 Hz P-C=C). ^{31}P NMR (202.4 MHz; CDCl_3) δ 23.59 ($\text{Ph}_3\text{P}^+\text{-C}$).

3.4 Preparation of dimethyl 2-(2-mercapto-2-thiazolin-3-yl)-3-(triphenylphosphanylidene) butanedioate (**6a**)

White powder (0.49 g, 95%), mp 154–156 °C; IR (ν_{max} , cm^{-1}) 1745, 1636 (C=O), 1431 (C=S); MS (m/z , %) 523 (M, 10), 464 (M - CO_2Me , 5), 405 (M - heterocyclic, 65), 262 (PPh_3 , 100), 183 (PPh_2 , 50), 118 (heterocyclic, 15), 108 (PPh , 41).

Major isomer (*E*)-**6a** (75%): ^1H NMR (500.1 MHz; CDCl_3) δ 3.13 and 3.78 (6H, 2s, 2 OCH_3), 3.16 (2H, m, CH_2N), 4.40 (2H, m, CH_2S), 5.41 (1H, d, $^3J_{\text{PH}}$ 17.5 Hz, P-C-CH), 7.49–7.67 (15H, m, 3 C_6H_5). ^{13}C NMR (125.8 MHz; CDCl_3) δ 28.15 (s, C-C-N), 41.28 (d, $^1J_{\text{PC}}$ 126.34 Hz, P=C), 49.24 (s, C-C-S), 52.57 and 54.01 (2s, 2 OCH_3), 61.37 (d, $^2J_{\text{PC}}$ 17.9 Hz, P-C-CH), 126.33 (d, $^1J_{\text{PC}}$ 92.1 Hz, C_{ipso}), 129.13 (d, $^3J_{\text{PC}}$ 12.2 Hz, C_{meta}), 132.36 (C_{para}), 133.47 (d, $^2J_{\text{PC}}$ 9.6 Hz, C_{ortho}), 169.82 (d, $^3J_{\text{PC}}$ 13.0 Hz, C=O), 171.07 (d, $^2J_{\text{PC}}$ 12.3 Hz, P-C=C), 195.13 (s, C=S). ^{31}P NMR (202.4 MHz; CDCl_3) δ 24.48 ($\text{Ph}_3\text{P}^+\text{-C}$).

Minor isomer (*Z*)-**6a** (25%): ^1H NMR (500.1 MHz; CDCl_3) δ 3.53 and 3.75 (6H, 2s, 2 OCH_3), 3.25 (2H, m, CH_2N), 4.56 (2H, m, CH_2S), 5.39 (1H, d, $^3J_{\text{PH}}$ 18.8 Hz, P-C-CH), 7.49–7.67 (15H, m, 3 C_6H_5). ^{13}C NMR (125.8 MHz; CDCl_3) δ 27.98 (s, C-C-N), 42.34 (d, $^1J_{\text{PC}}$ 139.4 Hz, P=C), 50.21 (s, C-C-S), 52.38 and 53.78 (2s, 2 OCH_3), 60.96 (d, $^2J_{\text{PC}}$ 17.5 Hz, P-C-CH), 125.67 (d, $^1J_{\text{PC}}$ 92.5 Hz, C_{ipso}), 129.13 (d, $^3J_{\text{PC}}$ 12.2 Hz, C_{meta}), 132.35 (C_{para}), 133.45 (d, $^2J_{\text{PC}}$ 9.9 Hz, C_{ortho}), 170.29 (d, $^3J_{\text{PC}}$ 17.9 Hz, C=O), 170.83 (d, $^2J_{\text{PC}}$ 13.5 Hz, P-C=C), 195.25 (s, C=S). ^{31}P NMR (202.4 MHz; CDCl_3) δ 25.24 ($\text{Ph}_3\text{P}^+\text{-C}$).

3.5 Preparation of diethyl 2-(2-mercapto-2-thiazolin-3-yl)-3-(triphenylphosphanylidene) butanedioate (**6b**)

White powder (0.51 g, 94%), mp 113–115 °C; IR (ν_{max} , cm^{-1}) 1745, 1634 (C=O), 1457 (C=S); MS (m/z , %) 551 (M, 3), 478 (M - CO_2Et , 5), 433 (M - heterocyclic, 10), 262 (PPh_3 , 100), 183 (PPh_2 , 43), 118 (heterocyclic, 10), 108 (PPh , 20).

Major isomer (*E*)-**6b** (70%): ^1H NMR (500.1 MHz; CDCl_3) δ 0.46 and 1.31 (6H, 2t, $^3J_{\text{HH}}$ 7.1 Hz and 7.3 Hz, 2 O-C- CH_3), 3.17 (2H, m, CH_2N), 3.46–4.30 (4H, 2m, 2 ABX_3 system, 2 OCH_2CH_3), 4.44 (2H, m, CH_2S), 5.39 (1H, d, $^3J_{\text{PH}}$ 17.8 Hz, P-C-CH), 7.48–7.69 (15H, m, 3 C_6H_5). ^{13}C NMR (125.8 MHz; CDCl_3) δ 13.91 and 14.29 (2s, 2 O-C- CH_3), 28.17 (s, C-C-N), 41.04 (d, $^1J_{\text{PC}}$ 126.1 Hz, P=C), 54.10 (s, C-C-S), 57.92 and 61.16 (2s, 2 O- $\text{CH}_2\text{-C}$), 61.39 (d, $^2J_{\text{PC}}$ 18.1 Hz, P-C-CH), 126.52 (d, $^1J_{\text{PC}}$ 92.1 Hz, C_{ipso}), 129.04 (d, $^3J_{\text{PC}}$ 11.7 Hz, C_{meta}), 132.27 (C_{para}), 133.56 (d, $^2J_{\text{PC}}$ 11.4 Hz, C_{ortho}), 169.36 (d, $^3J_{\text{PC}}$ 13.1 Hz, C=O), 170.22 (d, $^2J_{\text{PC}}$ 12.3 Hz, P-C=C), 195.00 (s, C=S). ^{31}P NMR (202.4 MHz; CDCl_3) δ 24.48 ($\text{Ph}_3\text{P}^+\text{-C}$).

Minor isomer (*Z*)-**6b** (30%): ^1H NMR (500.1 MHz; CDCl_3) δ 1.17 and 1.20 (6H, 2t, $^3J_{\text{HH}}$ 7.1 Hz and 7.4 Hz, 2 OCH_2CH_3), 3.27 (2H, m, CH_2N), 3.45–4.32 (4H, 2m, 2 ABX_3 system, 2 OCH_2CH_3), 4.60 (2H, m, CH_2S), 5.37 (1H, d, $^3J_{\text{PH}}$ 19.2 Hz, P-C-CH), 7.48–7.69 (15H, m, 3 C_6H_5). ^{13}C NMR (125.8 MHz; CDCl_3) δ 14.85 and 15.29 (2s, 2 O-C- CH_3), 27.78 (s, C-C-N), 42.22 (d, $^1J_{\text{PC}}$ 127.1 Hz, P=C), 53.93 (s, C-C-S), 58.51 (s, OCH_2CH_3), 60.84 (d, $^2J_{\text{PC}}$ 17.2 Hz, P-C-CH), 61.24 (s, OCH_2CH_3), 125.89 (d, $^1J_{\text{PC}}$ 92.3 Hz, C_{ipso}), 128.53 (d,

$^3J_{\text{PC}}$ 10.1 Hz, C_{meta}), 132.26 (C_{para}), 133.47 (d, $^2J_{\text{PC}}$ 10.6 Hz, C_{ortho}), 169.92 (d, $^3J_{\text{PC}}$ 12.0 Hz, C=O), 170.04 (d, $^2J_{\text{PC}}$ 12.2 Hz, P-C=C), 195.18 (s, C=S). ^{31}P NMR (202.4 MHz; CDCl_3) δ 25.42 ($\text{Ph}_3\text{P}^+\text{-C}$).

3.6 Preparation of di-tert-butyl 2-(2-mercapto-2-thiazolin-3-yl)-3-(triphenylphosphanylidene) butanedioate (6c)

White powder (0.58 g, 96%), mp 105–107 °C; IR (ν_{max} , cm^{-1}) 1739, 1641 (C=O), 1456 (C=S); MS (m/z , %) 607 (M, 5), 506 (M-CO₂t-Bu, 5), 262 (PPh₃, 100), 183 (PPh₂, 56), 118 (heterocyclic, 15), 108 (PPh, 30).

Major isomer (*E*)-**6c**: ^1H NMR (500.1 MHz; CDCl_3) δ 0.94 and 1.53 (18H, 2s, 2 CMe₃), 3.15 (2H, m, CH₂N), 4.04 (2H, m, CH₂S), 5.19 (1H, d, $^3J_{\text{PH}}$ 18.2 Hz, P-C-CH), 7.47–7.69 (15H, m, 3 C₆H₅). ^{13}C NMR (125.8 MHz; CDCl_3) δ 28.04 (s, C-C-N), 28.21 and 28.34 (2s, 2 CMe₃), 40.49 (d, $^1J_{\text{PC}}$ 126.7 Hz, P=C), 54.15 (s, C-C-S), 61.98 (d, $^2J_{\text{PC}}$ 17.2 Hz, P-C-CH), 77.67 and 81.05 (2s, 2 OCM₃), 127.10 (d, $^1J_{\text{PC}}$ 91.9 Hz, C_{ipso}), 128.85 (d, $^3J_{\text{PC}}$ 12.3 Hz, C_{meta}), 132.11 (d, $^4J_{\text{PC}}$ 2.5 Hz, C_{para}), 133.60 (d, $^2J_{\text{PC}}$ 9.7 Hz, C_{ortho}), 168.76 (d, $^3J_{\text{PC}}$ 12.2 Hz, C=O), 168.74 (d, $^2J_{\text{PC}}$ 12.2 Hz, P-C=C), 194.47 (s, C=S). ^{31}P NMR (202.4 MHz; CDCl_3) δ 24.06 ($\text{Ph}_3\text{P}^+\text{-C}$).

Acknowledgement

We gratefully acknowledge financial support from the Research Council of the University of Sistan and Balouchestan.

References

- [1] A.W. Johnson. *Ylid Chemistry*, Academic Press, New York (1966).
- [2] J.I.G. Cadogan. *Organophosphorus Reagents in Organic Synthesis*, Academic Press, New York (1979).
- [3] R. Engel. *Synthesis of Carbon-phosphorus Bonds*, CRC Press, Boca Raton, FL (1988).
- [4] H.R. Hudson. *The Chemistry of Organophosphorus Compounds, Vol. 1. Primary, Secondary and Tertiary Phosphines and Heterocyclic Organophosphorus(III) Compounds*, F.R. Hartley (Ed.), pp. 382–472, Wiley, New York (1990).
- [5] D.E.C. Corbridge. *Phosphorus: An Outline of Chemistry, Biochemistry and Uses*, Studies in Inorganic Chemistry, Vol. 20, 5th Edition, Elsevier, Amsterdam (1995).
- [6] O.I. Kolodiazhnyi. *Russ. Chem. Rev.*, **66**, 225 (1997).
- [7] R.A. Cherkasov, M.A. Pudovik. *Russ. Chem. Rev.*, **63**, 1019 (1994).
- [8] K.M. Pietrusiewicz, M. Zablocka. *Chem. Rev.*, **94**, 1375 (1994).
- [9] B.E. Maryanoff, A.B. Rietz. *Chem. Rev.*, **89**, 863 (1989).
- [10] K.C. Nicolaou, M.W. Harter, J.L. Gunzner, A. Nadin. *Liebigs Ann.*, 1283 (1997).
- [11] Y. Shen. *Acc. Chem. Res.*, **31**, 584 (1998).
- [12] A.A. Esmaili, M. Ghereghloo, M.R. Islami, H.R. Bijanzadeh. *Tetrahedron*, **59**, 4785 (2003).
- [13] T.L. Gilchrist. *Heterocyclic Chemistry*, Wiley, New York (1985).
- [14] E. Breitmaier, W. Voelter. *Carbon-13 NMR Spectroscopy: High-Resolution Methods and Applications in Organic Chemistry and Biochemistry*, 3rd Edition, VCH, Weinheim (1987).